Glenmark Spins Out Innovation With New US Base
Executive Summary
Glenmark’s innovation business will now be housed in a spin-out arm, based in the US, where the Indian parent believes the ecosystem is more conducive to cutting-edge R&D. The new structure could also potentially provide new opportunities to unlock value for the parent company.
You may also be interested in...
Glenmark’s Ichnos Debuts, With The Spirit Of Start-Up
Glenmark’s innovation spin-out Ichnos aims to rapidly advance its pipeline candidates and key data readouts next year are expected to shape the new entity’s growth trajectory and proposed funding initiatives.
Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation
Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.
Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation
Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.